Renalytix PLC

2O9

Company Profile

  • Business description

    Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.

  • Contact

    2 Leman Street
    LondonE1W 9US
    GBR

    T: +44 2079338790

    https://www.renalytix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Health Information Services

    Fiscal Year End

    30 June 2026

    Employees

    47

Stocks News & Analysis

stocks

Navigating the ASX dividend landscape in 2026

Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks

Meta stock has struggled amid AI spending concerns. Is it a buy?

Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks

Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth

We think Netflix stock is moderately overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,172.5012.400.14%
CAC 408,148.8979.720.99%
DAX 4024,856.47295.491.20%
Dow JONES (US)49,414.01336.780.69%
FTSE 10010,150.0511.960.12%
HKSE26,629.9644.900.17%
NASDAQ23,431.78206.950.89%
Nikkei 22553,688.89914.251.73%
NZX 50 Index13,556.8717.06-0.13%
S&P 5006,913.9738.350.56%
S&P/ASX 2008,848.7012.800.14%
SSE Composite Index4,122.585.640.14%

Market Movers